Veru Inc. (VERU)
VERU trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2024-09-30, https://www.sec.gov/Archives/edgar/data/863894/000143774924037576/0001437749-24-037576-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-09-30.
Profile
| Field | Value |
|---|---|
| Ticker | VERU on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000863894 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | WI |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $16.9M |
| Net income | -$37.8M |
| Operating income | -$36.2M |
| Net margin | -223.9% |
| Operating margin | -214.2% |
| Revenue growth | +3.6% |
| Cash | $24.9M |
| Total assets | $60.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months subsequent to the issuance date of these financial statements. 10 Table of Contents Note 3 Discontinued Operations On December 30, 2024, the Company and PCHC Limited (collectively, the Sellers ) entered into a Stock and Asset Purchase Agreement (the Purchase Agreement ) " | 10-Q 2026-08-10 |
| Cash and burn | $23.9M cash; operating cash flow -$6.5M a quarter. | Report 2026-06-30 |
| Shares outstanding | 17,050,320 (2026-08-06); 14,650,392 a year earlier; 90,280,439 three years earlier. 3y figure adjusted for split (1-for-10 overall). | Cover page 2026-08-06 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2025-08-11 | Source 2025-08-11 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-07-02 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Cherry Bekaert LLP, Atlanta, Georgia, United States | PCAOB Form AP 2025-12-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $5K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-06-30 | Not filed | -$7.0M | -$5.5M | $23.9M | No debt tags | Needs four quarters | 10-Q 2026-08-10 |
| Q2 2026 2026-03-31 | Not filed | -$2.7M | -$8.9M | $27.6M | No debt tags | Needs four quarters | 10-Q 2026-08-10 |
| Q1 2026 2025-12-31 | Not filed | -$5.3M | -$6.2M | $33.0M | No debt tags | Needs four quarters | 10-Q 2026-08-10 |
| Q4 2025 2025-09-30 | Not filed | $1.5M | -$5.5M | $15.8M | No debt tags | Needs four quarters | 10-K 2025-12-17 |
| Q3 2025 2025-06-30 | $0 | -$7.3M | -$5.5M | $15.0M | No debt tags | Needs four quarters | 10-Q 2025-08-12 |
| Q2 2025 2025-03-31 | $0 | -$7.9M | -$7.7M | $20.0M | No debt tags | Needs four quarters | 10-Q 2025-05-08 |
| Q1 2025 2024-12-31 | Not filed | -$8.9M | -$11.3M | $26.6M | No debt tags | Needs four quarters | 10-Q 2026-08-10 |
| Q4 2024 2024-09-30 | $6.7M | -$8.5M | -$4.4M | $24.9M | No debt tags | $16.9M | 10-K 2024-12-16 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-07-02 |
| Latest annual report FORM 10-K | 10-K | 2025-12-17 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-08-10 |
| Latest current report | 8-K | 2026-09-08 |
| Latest proxy | DEFA14A | 2026-01-28 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.4% |
| 1 month | -4.6% |
| 3 months | -22.6% |
| Year to date | -2.3% |
| 1 year | -16.7% |
| From 52-week high | -50.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TELO | Telomir Pharmaceuticals Inc. | $0.4810 | -1.96% | $35.4M |
| OSTX | OS Therapies Incorporated | $0.6807 | -8.63% | $35.4M |
| ATHE | Alterity Therapeutics Limited | $1.96 | 0.00% | $35.7M |
| RNTX | Rein Therapeutics Inc. | $0.4000 | -27.55% | $34.5M |
| GRCE | Grace Therapeutics Inc. | $1.75 | -3.31% | $36.8M |
| SER | Serina Therapeutics Inc. | $1.42 | +2.16% | $37.7M |
| BMEA | Biomea Fusion Inc. | $0.5201 | -10.67% | $37.8M |
| HYPD | Hyperion DeFi Inc. | $2.47 | -4.26% | $38.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier